Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges

VOL-10
|
ISSUE-02
|
2022
www.insightssuccess.com
The 10
Companies
ToWatchin2022
Most
Emerging
Emerging
Emerging
Biotech
Engineering Biology to Solve
Societal Challenges
Evozyne
Jeff Aronin,
Chairman
Evozyne

Way to save the life of every individual.
The cure to life
is Biotechnology

Embarking on
the Prospects
to Foster
Bio-Innovations
Editor’s Desk
Abhishek Joshi
Abhishek Joshi

iotechnology has become a major engine for
Bnational and urban competitiveness in the twenty-
first century. Biotechnology is being explored as a
crucial development for future advancements and growing
competition for policymakers.
It has always been a knowledge-driven sector because of its
consistency in comprehensively working to create value,
decoding genomics and proteomics and being a
paradigmatic knowledge-based economic activity.
Biotechnology industries are also among the most
innovative and important economic drivers in the modern
business world.
However, the biotechnology market has raised expectations
among investors, workers, and consumers. This is partly
related to the COVID-19 pandemic, which motivated the
acceleration in investments in the sector so commonly
characterized by its long-term results. Biotech industry
trends have revolved around diversifying the production of
patents and investing a lot of capital without expecting
short and mid-term results—a typical script regarding the
sector that could hold onto investors.
Eventually, this requires considering how they can scale up
and what is required, in order to deliver on their promise of
providing innovative medicines to patients. Early in the life
cycle, a biotech company's management team typically
grows the business through a few core assets and limited
programmers, focusing its resources where the most value
can be gained, such as differentiation in manufacturing,
understanding of disease and biology, or drug chemistry.
One of the important aspects that have been significantly
contributing to core drivers of longer-term success is
building a portfolio of products to sustain growth – this
research seeks to identify which portfolio approaches have
enabled biotech to scale its progress, stimulate innovation
for patients and created financial success for investors and
founders.
To further succeed in the niche, emerging companies try to
create an "end-to-end" entity from research and
development to commercialization, bringing their
product(s) to market themselves. Moreover, ensuring the
R&D profile continues to be the focus of most other biotech
companies' attention remains a primary aim for these
biotech companies.
Among those who are R&D-focused, some adopt a
"diversify approach," resulting in a significant increase in
the number of assets across multiple therapeutic areas and
relying heavily on revenue generated through collaboration
agreements to advance assets past pre-clinical and Phase 1
stages.
Embracing the ascending odyssey of the starlets that are
enabling transformations in the biotech industry, Insights
Success features the triumph trail of "The 10 Most
Emerging Biotech Companies to Watch in 2022.”
Flip through the pages and read on to comprehend the
immersive advancements that are being driven by a vision
to empower limitless ennoblements in the global healthcare
industry.
Have a Delightful Read!

Cover Story
08
16 20
Engineering Biology to Solve Societal Challenges
Evozyne
26
Evozyne

22 28
Golden Helex
Providing Leading Genomic Data
Analysis Software
32 36
38 40

sales@insightssuccess.com
October, 2022
Editor-in-Chief
Senior Sales Manager Business Development Manager
Marketing Manager
Technical Head
Technical Specialist Digital Marketing Manager
Research Analyst
Database Management Technology Consultant
Marry D'Souza
Managing Editor Executive Editor Assistant Editors
Visualizer
David King
Art & Design Director Associate Designer
Kshitij S Peter Collins
John Matthew
Sales Executives
David, Martin
Business Development Executives
Steve, Joe
Jacob Smile
Amar Sawant Dominique T.
SME-SMO Executive
Renuka Kulkarni Frank Adams
Circulation Manager
Robert Brown Stella Andrew David Stokes
Copyright © 2022 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any
form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success.
Reprint rights remain solely with Insights Success.
Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess
We are also available on :
Abhishek Joshi
Revati Badkas
Jenny Fernandes Anish Miller
Sandeep Tikode

Brief
Company Name
3Scan is turning tissue biology and histopathology into data
science, giving researchers the insights they need to break new
ground.
Featured Person
Todd Hulman,
CEO & Co-founder
3Scan
3scan.com
ClinCapture is revolutionizing the clinical trial industry with
Virtual Data Capture® and is the only provider of VDC®, a
leading-edge suite of products designed to expedite remote and
decentralized clinical trials.
Scott Weidley,
President & CEO
ClinCapture c
lincapture.com
CMIC is an innovative and unique provider of high-quality
solutions for the healthcare industry.
We create value by accelerating the access to therapies that
improve patients’ lives.
Jenny Lin,
COO & Board of Director
CMIC Inc
en.cmicgroup.com
Evozyne combines evolution and deep learning technology to
create highly functional novel proteins — Natural Machines™
— to solve longstanding challenges in therapeutics and
sustainability.
Jeff Aronin,
Chairman
Evozyne
evozyne.com
Golden Helix has been delivering industry-leading
bioinformatics solutions for over 20 years with 1,000s of users
around the world.
Andreas Scherer,
President & CEO
Golden Helixh
goldenhelix.com
Janrain is the first choice of global enterprises for mission-
critical customer identity and access management (CIAM)
needs.
Jim Kaskade,
CEO
Janrain
janrain.com
Metrendalytics Consulting, focused on helping companies
develop highly customized and flexible business intelligence
solutions.
Jan Miotto,
President
Metrendalytics
metrendalytics.com
The organization aims to deliver excellent clinical development
services and innovative resourcing solutions that let our clients
complete their clinical trials in an efficient and cost-effective
manner.
Sharon Hilton,
COO & Kristy Nichols,
CEO
Peachtree BioResearch
Solutions
peachtreebrs.com
Triox Nano Ltd(Israel) is an innovative bio-technology
company developing programmable biologic nano carriers that
are able to accurately deliver payloads to their target.
Roy Farfara,
Founder & CTO
Triox Nano
The 10
Companies
ToWatchin2022
Most
Emerging
Emerging
Emerging
Biotech
Biotech
Biotech

Engineering Biology to Solve Societal Challenges
C o v e r S t o r y
If nature is the world's
best engineer, imagine
what it can do if it's
fast-forwarded by a few
million years.
Evozyne
-Jeff Aronin, Chairman, Evozyne

echnical advancements in genetics and
Tsupercomputing are driving an astonishing amount
of scientific progress, colloquially known as the
biology revolution. The advances come at a fortuitous time.
Environmental threats are chipping away at the quality of
life for millions, while new viral illnesses continue to
emerge and thousands of known diseases lack effective
treatments.
Evozyne, founded by Paragon Biosciences, was created
on the premise that the new-found ability to create high-
performance proteins can deliver solutions to the some of
most intractable modern problems. The company believes
that by learning from evolution, it is possible to engineer
future-proofed interventions for patients and address
environmental challenges in carbon capture and energy
storage.
To learn more about its biology-based advancements, we at
Insights Success crossed paths with Evozyne's team, and in
the following interview, the company outlines its
pathbreaking vision to benefit humanity.
Below are the highlights of the interview.
What was the initial idea behind the inception of
Evozyne?
Evozyne was founded by Paragon Biosciences to advance
boundary-breaking biology from the laboratory and into the
real world, where it can solve complex problems.
Believing that the engineered proteins will dramatically
accelerate scientific breakthroughs, in two years we
recruited a world-class team of nearly 100 computational
scientists, researchers, and commercial leaders to conduct a
series of validation projects from Evozyne's new 30,000-
square-foot lab in Chicago.
Evozyne's evolution-based design is about encapsulating
vital information from the evolutionary history of a protein
into a computationally defined latent space that enables
rational design of natural-like proteins. When combined
with an iterative design-build-test approach, the models
generate protein designs that far exceed performance of
natural proteins and can be deployed in in real-world
applications.
In an early project, Evozyne partnered with Takeda, the
Japanese pharmaceutical company, to improve the
therapeutic potential of a specific target to treat a severe
genetic disease. This inherited disorder causes a dangerous
build-up of phenylalanine when a person eats protein or
foods containing aspartame, which severely alters their
quality of life.
Evozyne delivered an engineered enzyme that greatly
exceeded Takeda's design specifications, which led to an
initial multi-asset licensing agreement worth up to $400
million plus potential royalties from any commercial
product resulting from the collaboration. Our technology
outperformed expectations in this critical test and resulted
in an important collaboration for both companies. We are
hopeful this partnership with Takeda will lead to new
treatments that significantly improve the quality of life for
patients.
What are the primary objectives and philosophy of
Evozyne?
We believe boundary-breaking biology is the key to
transformational applications in therapeutics and
sustainability. Understanding that nature is the original and
best engineer, we use deep evolutionary learning in the lab
to understand millions of years of evolution.
By using evolution-based design, we're able to tackle some
of society's biggest challenges, like finding treatments for
patients with untreated diseases and developing solutions
for sustainability concerns.
Philosophically, we are highly pragmatic and our design-
build-test approach is applied to every aspect of our work.
We partner with like-minded entities, working together to
find world-changing solutions.
To realize the impact and potential of our engineered
proteins, we need partners who share our vision for a better
world and a commitment to the breakthrough approaches
required to get there. Our next-generation proteins can be
tailored across functions, and our efficient design-build-test
cycles enable commercial-scale solutions that unlock new
products and IP for our partners.
What are your key offerings that have a foothold in the
industry?
Evozyne began by combining artificial intelligence,
specifically machine learning, with applied biology to
accelerate scientific discovery. The process speeds up lead
identification for new medicines, which can result in
findings that support investigational new drug applications
and biologic license applications for experimental
The 10 Most Emerging Biotech Companies To Watch in 2022

therapeutics. From a timeline point of
view, Evozyne works from the earliest points,
identifying and optimizing lead targets, and continues its
work through developing experimental therapeutics and
supporting them through Phase 3 clinical trials.
Currently, we are creating high-performance enzymes for
our partners at Takeda and developing antibody, gene
optimization, and CRISPR technology platforms that we
believe will lead to the development of breakthrough
therapeutics for patients.
On the sustainability side, protein engineering moves the
science beyond traditional chemical catalysts by developing
enzymes that can withstand industrial conditions,
functioning in high-temperature conditions, and
overcoming pH resistance.
Our lead sustainability candidate is engineered to perform
at temperatures above 260 degrees Fahrenheit in an
industrial setting. Until now, no enzyme has been able to
function in the conditions
associated with power generation.
Our tests indicate that we have a product that meets the
challenge of enzymatic on-site carbon capture, which
means if successful the CO from power generation is never
2
released into the atmosphere. We look forward to proving
its performance, ﬁrst at the University of Kentucky this year
and later at the National Carbon Capture Center in
Alabama.
What are the roadblocks that Evozyne faces in the ever-
changing landscape of the business world?
Science is unpredictable, and it's hard. Those two facts, plus
the competitive nature of biotech businesses, make it
tempting to rush products to market. There are notable
examples of synthetic biology companies that gave in to
that temptation, sold products that didn't perform as billed
and subsequently failed.

Evozyne followed those stories closely, and our team is
committed to doing things differently. Our highly
pragmatic, design/built/test model requires us to repeatedly
prove to ourselves, with objective data, that the technology
performs as expected in real-world conditions. Evozyne
will bring products to market when and if they are proven
to a high level of certainty.
Being first can be a disadvantage if you fail to meet market
expectations. Protecting our reputation is a top priority for
Evozyne, and that means making sure we've done the hard
work to prove the performance of our technology platforms.
Beyond reputation management, recruiting top scientific
talent is a hurdle for many biotech companies. Fortunately,
Evozyne has proven its ability to hire top talent, which we
attribute to our pragmatic approach, the impact of the
problems we're working to solve, and the financial health of
our company. It helps that Chicago is a world-class city,
with globally renowned universities and a thriving
ecosystem that supports emerging biotech and pharma
companies. The scientific talent we need to succeed wants
to work here and, more
important, is happy
living here.
How is your company adapting to market orientation?
Nearly half of the world's disease burden will be addressed
by biology in the next 20 years. With that in mind, we're
pursuing life-changing treatments for patients and finding
ways to improve life for patients with diseases that aren't
currently treatable. There are more than 10,000 diseases for
which no medicine exists, and we hope to be part of the
solution for patients who lack options.
On the sustainability side, we're working to address climate
change with an on-site solution for carbon capture. We're
uncovering new paths to replace harmful plastics and
addressing global warming by making carbon capture a
reality. Our goal is to build high-performance proteins, with
exceptionally advanced functionality that makes what's
possible a reality. They are designed to be consistent with
the laws of nature and match the complex character of
natural environments, enabling biology-based solutions that
open our imagination to what's possible in solving some of
society's most intractable problems.
What is your approach to implementing innovative
technologies?
It's important to understand
that the protein sequence

space is impossibly large—much larger than the number of
atoms in the known universe—and no existing approach
can comprehensively search it.
Yet that's where we believe we'll find answers to the world's
most pressing scientific questions.
Our machine learning models help us find evolvable
proteins from that vast space that can be engineered to meet
real world challenges. More importantly, we learn from
every sequence generated in the design process, not just
from the ones that work.
Evozyne generates genotype-phenotype mapping for every
sequence generated, adding to our libraries and ability to
find desired solutions faster. The design rules uncovered
from these sequences help us simultaneously optimize
several protein functions. That's a whole lot more efficient
than optimizing one property at a time.
This functional innovation forms our design philosophy,
unlocking the natural potential of evolved proteins.
How does your company provide a societal benefit?
We're using science to solve some of the most complex
problems our society faces.
Think about it like this. Our platform is capable of creating
molecules that surpass the current limits of performance.
We can achieve targeted improvements in function that
mirrors the capabilities of natural evolution. If nature is the
world's best engineer, imagine what it can do if it's fast-
forwarded by a few million years.
What is the next chapter for Evozyne?
Our focus is on developing technology platforms for
therapeutics and sustainability. On the therapeutics side, the
focus is on gene optimization, gene editing, and future-
proofed antibodies.
Gene replacement therapy requires better-than-wildtype
performing genes to minimize dosing, maximize efficacy,
and reduce immunogenicity. Existing gene therapies are not
simultaneously optimized across all these dimensions.
Furthermore, certain diseases require replacement of genes
that are too large to fit into existing delivery technologies,
rendering them inaccessible.
Using our computational biology approach, we engineer
transgenes with superior performance in activity, affinity,
stability, and immunogenicity. In addition, Evozyne's
technology enables miniaturization of the gene cassette,
unlocking cures for previously inaccessible diseases.
Gene editing with CRISPR-Cas nucleases has introduced
new therapeutic modalities to treat a wide range of diseases.
Yet the existing nucleases are not specific enough and can
cause off-target editing, which means they edit the genome
in areas that are not intended.
By augmenting and redesigning the nucleases created by
nature, Evozyne is developing a comprehensive library of
highly specific Cas nucleases that can access most of the
genome. This combination of accessibility and specificity
will allow previously untreatable diseases to be cured safely
and effectively with our enzymes.
The Pandemic provided another complex problem that we
hope to solve. We all know that as viruses mutate, they
develop resistance to antibodies, rendering therapeutics
ineffective. The problem treating viral infection is one of
understanding the evolvability of the virus. Despite
widespread research, current discovery tools have limited
success in countering viral resistance.
Using our ability to understand the constraints on viral
evolution, Evozyne is developing an approach to generate
future-proofed, broadly neutralizing antibodies. Our first
application of this platform is a variant-resistant COVID-19
antibody.
Evozyne's sustainability practice is focused on carbon
capture and battery technology.
Capturing carbon at the point of production has been
inefficient and energy-intensive. Right now, it's too
expensive to reduce emissions. While naturally occurring
solutions can improve efficiency, they cannot withstand
harsh industrial conditions and can't perform at high
temperatures.
Leveraging design rules encoded by nature, Evozyne is
developing a highly efficient organic catalyst that remains
stable in the required industrial conditions, making carbon
capture at the point of production cost-effective.

October 2022 | 16 | www.insightssuccess.com

Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges

Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges

Recommandé

Recommandé

Contenu connexe

Similaire à Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges

Similaire à Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges (20)

Plus de InsightsSuccess4

Plus de InsightsSuccess4 (20)

Dernier

Dernier (20)

Emerging Biotech Evozyne Engineering Biology to Solve Societal Challenges